Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Myriad Genetics (MYGN) over the last 12 years, with Q3 2025 value amounting to $7.5 million.

  • Myriad Genetics' Treasury Shares rose 4423.08% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 4423.08%. This contributed to the annual value of $5.3 million for FY2024, which is 2045.45% up from last year.
  • Myriad Genetics' Treasury Shares amounted to $7.5 million in Q3 2025, which was up 4423.08% from $7.6 million recorded in Q2 2025.
  • Myriad Genetics' Treasury Shares' 5-year high stood at $7.6 million during Q2 2025, with a 5-year trough of $3.1 million in Q4 2021.
  • Moreover, its 5-year median value for Treasury Shares was $4.6 million (2023), whereas its average is $4.8 million.
  • Per our database at Business Quant, Myriad Genetics' Treasury Shares surged by 7894.74% in 2021 and then crashed by 892.86% in 2025.
  • Quarter analysis of 5 years shows Myriad Genetics' Treasury Shares stood at $3.1 million in 2021, then grew by 19.35% to $3.7 million in 2022, then increased by 18.92% to $4.4 million in 2023, then grew by 20.45% to $5.3 million in 2024, then surged by 41.51% to $7.5 million in 2025.
  • Its Treasury Shares stands at $7.5 million for Q3 2025, versus $7.6 million for Q2 2025 and $5.1 million for Q1 2025.